{"id":"fluticasone-discus-250-g","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Muscle cramps"},{"rate":null,"effect":"Nervousness"},{"rate":"1-5","effect":"Oral candidiasis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fluticasone propionate is a potent inhaled corticosteroid that acts as a glucocorticoid receptor agonist in the lungs. It suppresses the production and release of inflammatory cytokines, chemokines, and adhesion molecules, thereby reducing airway inflammation, mucus production, and bronchial hyperresponsiveness. The Discus formulation is a dry powder inhaler delivering 250 µg per actuation for maintenance therapy of asthma and COPD.","oneSentence":"Fluticasone propionate is a corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator release.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:13:02.130Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma maintenance therapy"},{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT00908362","phase":"PHASE1","title":"Impact of Fluticasone and Salmeterol on Airway Dendritic Cells (DCs) in Smokers","status":"COMPLETED","sponsor":"University of Rostock","startDate":"2009-05","conditions":"Smoke-related Lung Diseases, Chronic Obstructive Pulmonary Disease","enrollment":45},{"nctId":"NCT00252863","phase":"PHASE3","title":"DESOLO - SiT Peri-Launch: A Comparison of Symbicort Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-12","conditions":"Asthma","enrollment":1600}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Fluticasone Discus 250 µg","genericName":"Fluticasone Discus 250 µg","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fluticasone propionate is a corticosteroid that reduces airway inflammation by binding to glucocorticoid receptors and suppressing inflammatory mediator release. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}